Japanese Antibody Firm Signs Agreement On Cancer Diagnosis Through Urine Samples
This article was originally published in PharmAsia News
Executive Summary
Kumamoto, Japan-based antibody maker, Trans Genic, announced July 8 that it had signed a licensing agreement with a test agent maker looking to make cancer diagnosis through urine samples. Until now, the licensee company has conducted clinical trials based on Trans Genic's research results, with a goal toward commercialization and obtaining manufacturing and marketing approval. It is said that the development has shown promising results. According to the agreement, Trans Genic will continue to charge to provide necessary antibodies for clinical development and production, and will receive milestone fees and royalties based on sales after the product is marketed and launched. (Click here for more - Japanese language
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.